About SPECTAlung

What is SPECTAlung?

SPECTAlung is the first ever European prospective fully annotated tumour samples Biobank and Biomarker analysis platform for genetic profiling of patients diagnosed with thoracic cancer.

Thoracic cancer includes lung : Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC); malignant pleural mesothelioma (MPM) and thymic malignancies (TM).

Every year in Europe an estimated 409.900 persons of both genders are newly diagnosed with lung cancer and 353.500 will die of the disease in the same year. (Source EJC 2013)

Malignant Pleural Mesothelioma is a rare tumor with an incidence of 1.25/100.000 in the UK and 1.1/100.000 in Germany. Within the next 20 years the incidence is expected to double in many countries (Source: Annals Oncology 2010)

Thymic malignancies are rare tumors with a reported overall age adjusted incidence of 0.2/100.000 a year.

(Source: Annals Oncology 2010)

This platform unique in its kind joins up clinical forces at a Pan-European level to develop personalized treatments based on the results of the tissue sampling analysis. Supported by a network of 18 main clinical centers with thoracic expertise in 12 countries, this initiative has the ultimate goal of enabling better access to treatment options. An estimated number of 500 patients for the first year and  500 < 1000 patients  are expected to be enrolled in the following years. To date, the EORTC is proud to announce that 24 patients have been enrolled since the official start of the biobank on 22 May 2015!

(Insert Chart ’15 spectalung participating sites)